Abstract: VS-4718, also known as PND-1186, is an oral, reversible, and highly selective small-molecule inhibitor of focal adhesion kinase (FAK). While clinical trials have explored its efficacy in hematological malignancies such as acute myeloid leukemia (AML) as well as various solid tumors, recent preclinical research has heavily focused on its application in aggressive solid malignancies, notably pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC). This review synthesizes current literature on VS-4718, highlighting its pharmacological activity, which includes dose-dependent cytotoxicity, radiosensitization, and the enhancement of oncolytic virotherapy. Mechanistically, VS-4718 exerts its effects by blocking FAK autophosphorylation at Tyrosine 397 (Tyr397), thereby impairing DNA repair, inducing G2/M cell cycle arrest, and disrupting critical oncogenic signaling axes such as GPER/STAT3 and IGF-1/YAP. Despite its modest efficacy as a monotherapy and its potential to antagonize viral replication at high doses, VS-4718 demonstrates significant promise when utilized in rationally designed combination therapies. Future perspectives emphasize the need for predictive biomarkers and optimized combination regimens to maximize its therapeutic potential.
1. Introduction
Focal adhesion kinase (FAK), encoded by the PTK2 gene, is a non-receptor tyrosine kinase that plays a critical role in regulating cellular processes essential for cancer development, including proliferation, survival, migration, angiogenesis, and the maintenance of the tumor microenvironment (TME) [1][2]. FAK is frequently overexpressed in highly aggressive cancers, such as pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC), where it is associated with poor clinical outcomes, therapy resistance, and metastatic spread [1][4].
VS-4718 (previously known as PND-1186) is a potent, orally bioavailable, and selective FAK tyrosine kinase inhibitor (TKI) [1]. It has entered Phase I clinical trials for the treatment of advanced solid tumors, metastatic cancers, and hematological malignancies, specifically acute myeloid leukemia (AML) [2]. Because FAK inhibitors have shown only modest clinical activity as monotherapies, current research is heavily focused on understanding the molecular mechanisms of VS-4718 and evaluating its efficacy in combination with other therapeutic modalities, such as radiotherapy, virotherapy, and targeted inhibitors [1][2].
2. Pharmacological Activity
VS-4718 exhibits significant pharmacological activity across multiple cancer models, primarily through the inhibition of tumor growth, depletion of cancer stem cell pools, and modulation of the tumor stroma [1].
In PDAC, VS-4718 demonstrates dose-dependent cytotoxicity across various cell lines (e.g., Panc-1, PSN-1, MIA PaCa-2, Capan-1, and Beta-TC-3), with IC50 values ranging from 1.23 μM to approximately 60.85 μM, depending on the inherent sensitivity of the cell line [1][2]. Beyond direct cytotoxicity, VS-4718 acts as a potent radiosensitizer. In 3D multicellular tumor spheroids and co-cultures with extracellular matrix (ECM)-producing pancreatic stellate cells, the combination of VS-4718 and radiotherapy significantly reduces tumor aggregate growth compared to radiation alone [1]. Furthermore, VS-4718 has been shown to enhance the oncolytic activity of the Coxsackievirus B3 (CVB3) strain PD-H. In sensitive PDAC cell lines, co-treatment with VS-4718 and PD-H results in synergistic or additive tumor cell lysis [2].
In TNBC, VS-4718 effectively suppresses tumor cell migration, colony formation, and spheroid expansion. It abolishes the migratory effects induced by estrogens and prevents the growth stimulatory responses triggered by the IGF-1/IGF-1R signaling system in aggressive TNBC cell lines such as MDA-MB 231 and SUM159 [3][4].
3. Molecular Mechanism of Action
The primary mechanism of action of VS-4718 is the selective, reversible inhibition of FAK autophosphorylation at the Tyrosine 397 (Tyr397) residue, a critical step required for full FAK activation and downstream signaling [1][2]. By blocking this site, VS-4718 disrupts multiple oncogenic pathways:
DNA Repair and Cell Cycle Arrest: In PDAC models, FAK inhibition by VS-4718 impairs the DNA damage response following radiotherapy. It significantly increases the retention of γ-H2AX foci (a marker of DNA double-strand breaks) and arrests cancer cells in the radiosensitive G2/M phase of the cell cycle [1].
Tumor Microenvironment Modulation: VS-4718 directly targets the tumor stroma by reducing the viability of pancreatic stellate cells and markedly inhibiting their production of ECM components, such as collagen. This disruption of the ECM-integrin-FAK signaling axis deprives cancer cells of stroma-derived survival signals [1].
GPER/STAT3 Axis: In TNBC, estrogenic signaling via the G-protein coupled estrogen receptor (GPER) activates FAK. VS-4718 blocks this activation, thereby preventing the nuclear accumulation of the transcription factor STAT3 and the subsequent expression of target genes involved in cancer progression, such as c-FOS, EGR1, and CTGF [3].
IGF-1/YAP Axis: VS-4718 also intercepts the Hippo signaling pathway in TNBC. Activation of the IGF-1/IGF-1R system normally promotes FAK-dependent nuclear translocation of YAP (Yes-associated protein). VS-4718 inhibits this process, suppressing YAP/TEAD transcriptional activity and downregulating target genes like CTGF and Cyr61, which are essential for tumor growth and survival [4].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail the specific chemical modifications and corresponding structure-activity relationship (SAR) data for VS-4718, it identifies the compound as a highly selective, reversible small-molecule inhibitor targeting the kinase domain of FAK [1]. At micromolar concentrations, VS-4718 exhibits high specificity for FAK, with negligible off-target activity except against PYK2 (a kinase closely related to FAK that is also involved in tumor cell proliferation) and FLT3 [1][2]. The cross-reactivity with FLT3, a receptor tyrosine kinase predominantly expressed in cells of hematopoietic origin, provides a mechanistic rationale for the clinical evaluation of VS-4718 in hematological malignancies such as AML [1][2].
5. Current Limitations
Despite promising preclinical data, the clinical translation of VS-4718 faces several limitations. First, as a monotherapy, FAK inhibitors have demonstrated only modest clinical efficacy, characterized by low rates of partial responses and disease stabilization in patients with advanced solid malignancies [2]. Second, there is significant heterogeneity in treatment response; for instance, PDAC cell lines like MIA PaCa-2 exhibit marked resistance to VS-4718, requiring very high doses to achieve cytotoxicity [1][2]. Finally, in the context of combination therapies with oncolytic viruses, VS-4718 has been shown to dose-dependently inhibit viral replication. At high concentrations, this suppression of viral replication antagonizes the oncolytic efficacy of the virus, negating the benefits of the combination approach [2].
6. Future Perspectives
To overcome current limitations, the future clinical utility of VS-4718 relies heavily on rationally designed combination therapies. Combining VS-4718 with radiotherapy, chemotherapy, or immune checkpoint inhibitors can exploit its ability to modulate the tumor microenvironment and impair DNA repair [1][2]. When combined with virotherapy, optimizing treatment regimens—such as utilizing sequential rather than simultaneous administration—may prevent the FAK inhibitor from suppressing viral replication while still sensitizing the tumor cells [2]. Additionally, the identification of predictive biomarkers (e.g., Merlin expression or specific genetic signatures) is crucial to distinguish responders from non-responders, thereby enabling personalized therapeutic strategies and minimizing the risk of treatment failure [1][2]. Further in vivo studies are also required to validate the synergistic effects observed in 3D multicellular models and to fully elucidate the impact of VS-4718 on the complex tumor-stroma interplay [1][2].
